List of insiders holdings for BeiGene, Ltd.:
  1. Shares directly owned by the insider.
  2. Shares indirectly owned by the insider.
  3. Total shares owned by the insider (sum of shares directly and indirectly owned).
  4. Total market value if available.
  5. Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Insider Holder NameReport
Date Time		Shares Owned
Directly
Indirectly		Total
Shares Owned		Filing
BAKER BROS. ADVISORS LP
14159 L.P.
Baker Bros. Advisors (GP) LLC
BAKER JULIAN
BAKER FELIX
667 L.P.
Baker Brothers Life Sciences LP
Director
10% Owner		2020-12-04 17:24:18154,315,490
0		154,315,490Form 13D
HHLR ADVISORS LTD.
HILLHOUSE INVESTMENT MANAGEMENT LTD.
10% Owner		2023-02-14 16:14:24147,043,058
0		147,043,058Form 13D
OYLER JOHN
Chief Executive Officer		2023-02-10 16:05:2170,026,397
0		70,026,397Form 13G
CB Biotech Investment Ltd
CPEChina Fund L.P.
CITIC PE Associates L.P.
CITIC PE Funds Ltd
10% Owner		2016-02-09 20:07:3519,601,138
0		19,601,138Form 4
AMGEN INC
10% Owner		2021-09-13 19:27:0718,943,802
0		18,943,802Form 4
BAKER BROS. ADVISORS LP
667 L.P.
BAKER JULIAN
BAKER FELIX
Baker Bros. Advisors (GP) LLC
Baker Brothers Life Sciences LP
Director
10% Owner		2022-06-24 16:46:1520,838
11,805,760		11,826,598Form 4
Wang Xiaodong
Chair, Scientific Advisory Brd		2023-03-20 17:37:485,445,112
5,358,962		10,804,074Form 4
Glazer Donald W.
Director		2022-06-24 17:38:182,805,866
0		2,805,866Form 4
Li Ji
EVP and Gl. Head of Bus. Dev.		2018-03-02 18:41:222,721,000
0		2,721,000Form 4
Wu Xiaobin
President, COO & GM China		2022-06-24 17:39:412,062,046
4000		2,066,046Form 4
Peterson Amy C.
CMO, Immuno-oncology		2018-12-19 18:34:101,966,402
0		1,966,402Form 4
Wang Lai
Global Head of R&D		2022-06-28 17:32:501,504,035
58,188		1,562,223Form 4
Liang Howard
CFO & Chief Strategy Officer		2021-06-30 16:45:491,553,149
0		1,553,149Form 4
Yan Wendy Xiaojun
Sr. VP, Head of Reg. Affairs		2016-07-15 16:30:50825,000
0		825,000Form 4
Yang Jianxin
Sr. VP, Head of Clinical Dev.		2016-07-15 16:34:25825,000
0		825,000Form 4
Huang Jane
CMO, Hematology		2021-12-16 17:50:15371,331
0		371,331Form 4
Wang Julia Aijun
Chief Financial Officer		2023-03-03 17:00:58237,003
0		237,003Form 4
Tang Ke
Director		2017-04-21 16:42:20199,992
0		199,992Form 4
Yuan RuiRong
Chief Medical Officer		2016-02-09 20:08:35130,000
0		130,000Form 4
Malley Thomas
Director		2022-06-24 17:37:2198,419
0		98,419Form 4
Sanders Corazon (Corsee) D.
Director		2022-06-24 17:37:3859,137
0		59,137Form 4
HOOPER ANTHONY C
Director		2022-06-24 17:38:4059,137
0		59,137Form 4
Riva Alessandro
Director		2022-06-24 17:38:0151,337
0		51,337Form 4
Dugan Margaret
Director		2022-06-24 17:39:2351,337
0		51,337Form 4
Chen Timothy Yung-Cheng
Director		2021-06-21 16:42:0825,298
0		25,298Form 4
su Jingshyh S
Director		2021-06-21 16:34:1225,298
0		25,298Form 4
Yi Qingqing
Director		2022-08-24 16:15:5824,492
0		24,492Form 4
KRISHANA RANJEEV
Director		2016-02-02 19:14:150
0		0Form 3
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Research GmbH
10% Owner		2018-02-13 16:29:070
0		0Form 13G
GOLLER MICHAEL
Director		2016-02-02 19:40:270
0		0Form 3